Streptococcus Pneumoniae Serotype 6B Conjugate Vaccine
This is a monovalent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae serotype 6b. The vaccine works by linking the capsular polysaccharide antigen to a diphtheria CRM197 protein carrier, which enhances immune response particularly in young children who typically have poor responses to polysaccharide antigens alone. It is used for active immunization to prevent invasive pneumococcal disease caused by serotype 6b.
A conjugate vaccine providing targeted protection against invasive pneumococcal disease from S. pneumoniae serotype 6b by linking polysaccharide antigen to a diphtheria protein carrier.
Key facts at a glance
- RxNorm
- 798230
- Generic
- Streptococcus Pneumoniae Serotype 6b Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Vaxneuvance, Prevnar 13
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease (including bacteremia, meningitis, and pneumonia) caused by Streptococcus pneumoniae serotype 6b. May be used in infants, young children, and high-risk populations who are susceptible to this specific pneumococcal serotype.
This conjugate vaccine combines the capsular polysaccharide antigen from S. pneumoniae serotype 6b with the nontoxic diphtheria CRM197 protein carrier. This conjugation converts a T-cell independent response into a T-cell dependent response, leading to improved immunogenicity, memory B-cell formation, and protective antibody production, particularly in young children.
Common adverse effects include injection site reactions (redness, swelling, pain), fever, and irritability in children. Contraindicated in individuals with severe hypersensitivity to any vaccine component. Like other pneumococcal vaccines, it does not protect against serotypes not included in the formulation or against non-pneumococcal pathogens. Healthcare providers should monitor for allergic reactions, especially in individuals with history of hypersensitivity to diphtheria toxoid or CRM197 protein.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy